Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of “Reduce” by Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned an average recommendation of “Reduce” from the six analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $14.00.

Several equities analysts have recently weighed in on IART shares. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $11.00 to $16.00 in a research note on Thursday, May 28th. Argus reiterated a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Wells Fargo & Company increased their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Truist Financial reduced their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $17.90 on Wednesday. The firm’s 50 day moving average price is $12.79 and its 200-day moving average price is $12.08. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $18.05. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The stock has a market capitalization of $1.39 billion, a PE ratio of -2.77, a price-to-earnings-growth ratio of 1.18 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter in the prior year, the business earned $0.41 EPS. The business’s quarterly revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Equities research analysts expect that Integra LifeSciences will post 2.44 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after acquiring an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Integra LifeSciences in the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. increased its holdings in Integra LifeSciences by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after acquiring an additional 35,790 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Integra LifeSciences by 23.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after acquiring an additional 45,693 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Integra LifeSciences in the 2nd quarter worth approximately $491,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.